Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Active, not recruiting · NCT02864992 · Registry updated 2026-07-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-07-14 | NCT02864992 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| EMD Serono Research & Development Institute, Inc. | 18 |
| Merck KGaA, Darmstadt, Germany | 31 |
176 results · Page 1 of 8
Research sites
Swipe the table sideways for more columns.